subject: Merck Kgaa: Pharmavitae Profile - Market Research Report On Aarkstore Enterprise [print this page] Introduction Introduction
This analysis examines the historical and forecast performance for Merck KGaA in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.
Features and benefits
Gain insight into Merck KGaAs strategic outlook across the next 6 years
Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source
Highlights
Strategic insight into the prospects for Merck KGaA over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the companys prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.
Your key questions answered
Benchmark Merck KGaAs performance against key rivals in the prescription pharmaceutical sector
See how Erbitux and six new launches will drive the companys sales growth
Assess the effects of Millipore on the companys non-prescription pharmaceutical sales
Table of Contents :
ABOUT DATAMONITOR HEALTHCARE 2
About the PharmaVitae team 2
Chapter 1 About this profile 3
PharmaVitae Explorer database 3
Chapter structure 3
Data sourcing 4
Chapter 2 Executive summary 5
Key findings 5
Prescription pharmaceutical sales and growth rate performance, 200315 6
Financial performance, 200315 7
Merck KGaA: PharmaVitae forecasts at a glance 8
Strategic insight 9
SWOT analysis 15
Chapter 3 Quarterly news update 23
Latest quarterly sales 23
Latest comment 23
Latest prescription pharma product news 24
Latest corporate news 29
Future product milestones 31
Chapter 4 Company introduction 32
Key findings 32
Background 33
Key corporate developments 33
M&A history 33
Current corporate structure 34
Chapter 5 Company sales 36
Key findings 36
Prescription pharmaceutical sales and growth rate analysis, 200315 37
Product analysis 38
Therapy area analysis 44
Geographic analysis 46
Launch/core/expiry analysis 48
Molecule type analysis 53
Externalization analysis 55
Chapter 6 Company financials 57
Key findings 57
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 200309 58
